Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2928.95, up by 30.05 points or 1.04% from its previous closing of Rs. 2898.90 on the BSE.

The scrip opened at Rs. 2898.00 and has touched a high and low of Rs. 2928.95 and Rs. 2898.00 respectively. So far 3083 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2954.45 on 26-Apr-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2954.45 and Rs. 2777.00 respectively. The current market cap of the company is Rs. 48140.86 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.46% and 13.66% respectively.

Dr Reddy's Laboratories has reportedly initiated a voluntary recall of anti-seizure drug Divalproex extended release tablets from the US market owing to cGMP deviations noticed in certain batches of the product.

According to the US Food and Drug Administration (USFDA) report, the company has started recalling of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April 11, 2019 after finding out that the product was exposed to humidity levels above 50 percent during packaging.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.